Vireo Growth (VREOF) Share-based Compensation (2020 - 2026)
Vireo Growth (VREOF) reported Share-based Compensation of $7.0 million for Q1 2026, up 438.46% on a YoY basis from $1.3 million in Q1 2025, and up 100.87% sequentially from $3.5 million in Q4 2025.
Vireo Growth (VREOF) Share-based Compensation (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Share-based Compensation data on file, last reported at $7.0 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 438.46% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $10.8 million (up 171.97% YoY), and the FY2025 full-year result was $12.9 million, up 265.96% from the prior year.
- Share-based Compensation advanced to $7.0 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $7.0 million in Q1 2026 to a low of -$60751.0 in Q2 2024.
- A 5-year average of $1.1 million and a median of $272259.5 in 2022 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 16205.1% in 2024, while the deepest fall reached 132.21% in 2024.
- Tracing VREOF's Share-based Compensation over 5 years: stood at $248629.0 in 2022, then slumped by 40.4% to $148183.0 in 2023, then jumped by 1326.37% to $2.1 million in 2024, then surged by 64.87% to $3.5 million in 2025, then surged by 100.87% to $7.0 million in 2026.
- Business Quant data shows VREOF's Share-based Compensation at $7.0 million in Q1 2026, $3.5 million in Q4 2025, and $121976.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.00 Mn |
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | 3.48 Mn |
| Dec 31, 2025 | 3.48 Mn |
| Sep 30, 2025 | 121,976.00 |
| Sep 30, 2025 | 121,976.00 |
| Jun 30, 2025 | 185,345.00 |
| Jun 30, 2025 | 185,345.00 |
| Mar 31, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 2.11 Mn |
| Dec 31, 2024 | 2.11 Mn |
| Sep 30, 2024 | 615,215.00 |
| Sep 30, 2024 | 615,215.00 |
| Jun 30, 2024 | -60,751.00 |
| Jun 30, 2024 | -60,751.00 |
| Mar 31, 2024 | 179,789.00 |
| Mar 31, 2024 | 179,789.00 |
| Dec 31, 2023 | 148,183.00 |
| Dec 31, 2023 | 148,183.00 |